News Novo Nordisk A/S Swiss Exchange

Equities

NOVOB

DK0062498333

Delayed Swiss Exchange Other stock markets 11:36:57 2023-09-07 am EDT			5-day change	1st Jan Change
80 ^CHF	+33.33%		-.--%	-.--%

Jun. 28	India plans incentives for diabetes, obesity drug makers in 2026, government official says	RE
Jun. 28	NOVO NORDISK : UBS gives a Neutral rating	ZD

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

India plans incentives for diabetes, obesity drug makers in 2026, government official says	Jun. 28	RE
NOVO NORDISK : UBS gives a Neutral rating	Jun. 28	ZD
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk	Jun. 27	MT
Top Midday Stories: Walgreens Shares Tumble on Lower Guidance, Store Closures; SM Energy, NOG to Buy XCL Resources; Uber, Lyft Worker Classification Heads to Massachusetts Ballot	Jun. 27	MT
Novo Nordisk to Limit Launch of Wegovy in China, Executive Says	Jun. 27	MT
NOVO NORDISK : JP Morgan gives a Buy rating	Jun. 27	ZD
The same old winners	Jun. 27
NOVO NORDISK : Goldman Sachs reiterates its Buy rating	Jun. 27	ZD
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	Jun. 26	MT
2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million	Jun. 26	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	Jun. 26	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	Jun. 26	MT
Sector Update: Health Care	Jun. 26	MT
European Equities Close Lower in Wednesday Trading	Jun. 26	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	Jun. 26	MT
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial	Jun. 26	MT
Novo Nordisk Halts Late-stage Hypertension, Kidney Disease Treatment Trial; DKK6 Billion Impairment Loss Expected	Jun. 26	MT
Novo Nordisk: trial failure and impact on results	Jun. 26	CF
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial	Jun. 26	MT
Novo Nordisk to Take $816 Million Impairment Charge After Stopping Clarion-CKD Trial	Jun. 26	MT